| pubmed-article:9176098 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0026473 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0038836 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0030685 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0162388 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0680255 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0391871 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C1283071 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C1963578 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0083632 | lld:lifeskim |
| pubmed-article:9176098 | lifeskim:mentions | umls-concept:C0530870 | lld:lifeskim |
| pubmed-article:9176098 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9176098 | pubmed:dateCreated | 1997-6-23 | lld:pubmed |
| pubmed-article:9176098 | pubmed:abstractText | Ceramide acts as an intracellular second messenger in cellular signal transduction. We examined the effects of two cell-permeable ceramides, C2-ceramide and C6-ceramide, on human monocyte functions. After monocytes were primed with lipopolysaccharide (LPS) or interferon-gamma (IFN-gamma) for 18 hr in suspension culture, they produced a high amount of superoxide (O2-) when triggered by phorbol myristate acetate. C2- or C6-ceramide inhibited O2- release from monocytes primed with LPS (1 ng/ml) or IFN-gamma (100 U/ml), but did not affect unprimed monocytes. An analogue, C2-dihydroceramide, was inactive. C2-ceramide was most effective at 6 microM, and C6-ceramide at 60 microM. C2- or C6-ceramide at these concentrations was not toxic for monocytes, as assessed by trypan blue exclusion and by the 3-[4, 5-dimethylthiazol-2-y1]-2,5 diphenyl tetrazolium bromide (MTT) assay which measures the ability of live cells to produce formazan. C2-ceramide (20 microM) had no effect on the killing of leukaemic cells (HL-60 and K562 cells) by monocytes treated with IFN-gamma, LPS, or both for 18 hr, with killing assessed by an 111 Indium-releasing assay. C2-ceramide (20 microM) induced secretion of low amounts of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) from the monocytes. But C2-ceramide did not alter the higher secretion of TNF-alpha or IL-1 beta from monocytes treated with IFN-gamma or LPS. Thus the cell-permeable ceramides acted like antagonists of LPS, rather than analogues of LPS, as has been proposed. The results here showed that the signal transduction pathway for O2- release by monocytes differed from that for the cytolysis of leukaemic cells, and confirmed that oxygen radicals are not involved in cytolysis. | lld:pubmed |
| pubmed-article:9176098 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9176098 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9176098 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9176098 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9176098 | pubmed:issn | 0019-2805 | lld:pubmed |
| pubmed-article:9176098 | pubmed:author | pubmed-author:PabstM JMJ | lld:pubmed |
| pubmed-article:9176098 | pubmed:author | pubmed-author:NakaboYY | lld:pubmed |
| pubmed-article:9176098 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9176098 | pubmed:volume | 90 | lld:pubmed |
| pubmed-article:9176098 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9176098 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9176098 | pubmed:pagination | 477-82 | lld:pubmed |
| pubmed-article:9176098 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:meshHeading | pubmed-meshheading:9176098-... | lld:pubmed |
| pubmed-article:9176098 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9176098 | pubmed:articleTitle | C2-ceramide and C6-ceramide inhibited priming for enhanced release of superoxide in monocytes, but had no effect on the killing of leukaemic cells by monocytes. | lld:pubmed |
| pubmed-article:9176098 | pubmed:affiliation | Department of Oral Biology, University of Tennessee, Memphis 38163, USA. | lld:pubmed |
| pubmed-article:9176098 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9176098 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9176098 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9176098 | lld:pubmed |
